892-P: Impact of ReCET Therapy on Continuous Glucose Monitoring (CGM) Metrics in Type 2 Diabetes—Insights from the REGENT-1 Trial
DAVID N. O'NEAL(Double Helix (United States)), Elif I. Ekinci(The University of Melbourne), Christopher Sorli(Double Helix (United States)), Bronte A. Holt(Double Helix (United States)), Adrian Sartoretto(Double Helix (United States)), Rhys Vaughan(Double Helix (United States)), Sujievvan Chandran(Double Helix (United States)), Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Georgina Cameron(Double Helix (United States)), John Apostolopoulos, Barham K. Abu Dayyeh(Mayo Clinic)
Cited by 0
Related Papers
Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial
|The Lancet|2022|311
Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24 Months Follow-Up
|Obesity Surgery|2017|231
Introduction and Methodology: <i>Standards of Care in Diabetes—2024</i>
|Diabetes Care|2023|184
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
|Nature Medicine|2024|152
SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission
|The Journal of Clinical Endocrinology & Metabolism|2019|122